comparemela.com

Latest Breaking News On - Vp research chemistry - Page 1 : comparemela.com

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi's strategic focus

Michigan state universityUnited statesEleanor perkinFrazer hallAdam golebiowskiBryce pilzNicolas beuzenMagdalena lickaSandi greenwoodOffice of the viceWarsaw stock exchangeInternational institute of molecularUniversity of michiganInnovation partnershipBusiness developmentVp research chemistry

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

/PRNewswire/ OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry.

Michigan state universityUnited statesEleanor perkinFrazer hallAdam golebiowskiNicolas beuzenBryce pilzMagdalena lickaSandi greenwoodOffice of the viceWarsaw stock exchangeUniversity of michiganInternational institute of molecularInnovation partnershipInnovation partnerships university of michiganBusiness development

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

/PRNewswire/ OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry.

Michigan state universityUnited statesEleanor perkinFrazer hallAdam golebiowskiNicolas beuzenBryce pilzMagdalena lickaSandi greenwoodOffice of the viceWarsaw stock exchangeUniversity of michiganInternational institute of molecularInnovation partnershipInnovation partnerships university of michiganBusiness development

vimarsana © 2020. All Rights Reserved.